KR20080027275A - 암의 치료를 위한 4-아닐리노-3-퀴놀린카르보니트릴 - Google Patents

암의 치료를 위한 4-아닐리노-3-퀴놀린카르보니트릴 Download PDF

Info

Publication number
KR20080027275A
KR20080027275A KR1020077030196A KR20077030196A KR20080027275A KR 20080027275 A KR20080027275 A KR 20080027275A KR 1020077030196 A KR1020077030196 A KR 1020077030196A KR 20077030196 A KR20077030196 A KR 20077030196A KR 20080027275 A KR20080027275 A KR 20080027275A
Authority
KR
South Korea
Prior art keywords
cancer
compound
pharmaceutically acceptable
formula
src
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020077030196A
Other languages
English (en)
Korean (ko)
Inventor
프랭크 찰스 보스첼리
Original Assignee
와이어쓰
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37575124&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20080027275(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 와이어쓰 filed Critical 와이어쓰
Publication of KR20080027275A publication Critical patent/KR20080027275A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020077030196A 2005-06-24 2006-06-13 암의 치료를 위한 4-아닐리노-3-퀴놀린카르보니트릴 Withdrawn KR20080027275A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69367105P 2005-06-24 2005-06-24
US60/693,671 2005-06-24

Publications (1)

Publication Number Publication Date
KR20080027275A true KR20080027275A (ko) 2008-03-26

Family

ID=37575124

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077030196A Withdrawn KR20080027275A (ko) 2005-06-24 2006-06-13 암의 치료를 위한 4-아닐리노-3-퀴놀린카르보니트릴

Country Status (20)

Country Link
US (1) US20070010527A1 (enExample)
EP (1) EP1893209A2 (enExample)
JP (1) JP2008546777A (enExample)
KR (1) KR20080027275A (enExample)
CN (1) CN101252931A (enExample)
AR (1) AR057403A1 (enExample)
AU (1) AU2006262591A1 (enExample)
BR (1) BRPI0611977A2 (enExample)
CA (1) CA2610209A1 (enExample)
CR (1) CR9539A (enExample)
EC (1) ECSP078015A (enExample)
GT (1) GT200600268A (enExample)
IL (1) IL187792A0 (enExample)
MX (1) MX2007016542A (enExample)
NI (1) NI200700323A (enExample)
NO (1) NO20076075L (enExample)
PE (1) PE20070323A1 (enExample)
RU (1) RU2007143434A (enExample)
TW (1) TW200730177A (enExample)
WO (1) WO2007001839A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2007148072A (ru) * 2005-07-01 2009-08-10 Вайет (Us) Кристаллические формы 4-[(2,4-дихлор-5-метоксифинил)амино]-6- меокси-7-[3-(4-метил-1-пиперазинил)пропокси]-3-хиналинкарбонитрил и способы их получения
WO2013187967A1 (en) 2012-06-15 2013-12-19 Institute For Cancer Research D/B/A The Research Institute Of Fox Case Cancer Center ("Fox Chase Cancer Center") Sensitization of cancer cells to dna damage by inhibiting kinases essential for dna damage checkpoint control
WO2017134679A1 (en) * 2016-02-03 2017-08-10 Msn Laboratories Private Limited Novel crystalline polymorphs of 4-[(2.4-dichioro-5-methoxvphenvl)aniinol- 6-methoxv-7-13-(4-methyl-l-piperazinvl)propoxvl-3-quinolinecarbonitrile and process for preparation thereof
CN107433391B (zh) * 2017-07-03 2020-01-17 武汉逸飞激光设备有限公司 一种基于图像识别的焊接校准方法及系统

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6432979B1 (en) * 1999-08-12 2002-08-13 American Cyanamid Company Method of treating or inhibiting colonic polyps and colorectal cancer
US6384051B1 (en) * 2000-03-13 2002-05-07 American Cyanamid Company Method of treating or inhibiting colonic polyps
UA77200C2 (en) * 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
RU2006113691A (ru) * 2003-11-06 2007-12-20 Вайет (Us) Применение 4-анилин-3-хинолинкарбонитрилов для лечения хронической миелогенной лейкемии (cml)

Also Published As

Publication number Publication date
NO20076075L (no) 2008-03-18
MX2007016542A (es) 2008-03-04
IL187792A0 (en) 2008-11-03
CR9539A (es) 2008-02-20
NI200700323A (es) 2008-06-25
WO2007001839A2 (en) 2007-01-04
AU2006262591A1 (en) 2007-01-04
WO2007001839A3 (en) 2007-04-26
ECSP078015A (es) 2008-01-23
JP2008546777A (ja) 2008-12-25
CN101252931A (zh) 2008-08-27
EP1893209A2 (en) 2008-03-05
PE20070323A1 (es) 2007-05-04
AR057403A1 (es) 2007-12-05
US20070010527A1 (en) 2007-01-11
BRPI0611977A2 (pt) 2010-10-13
RU2007143434A (ru) 2009-07-27
GT200600268A (es) 2007-06-18
TW200730177A (en) 2007-08-16
CA2610209A1 (en) 2007-01-04

Similar Documents

Publication Publication Date Title
Burbridge et al. S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab
JP4989476B2 (ja) 血管新生阻害物質の効果を検定する方法
US7919625B2 (en) 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML)
US20090162286A1 (en) Phosphodiesterase 10 Inhibition as Treatment for Obesity-Related and Metabolic Syndrome-Related Conditions
US8710068B2 (en) Method of treating cancer using a survivin inhibitor
KR20030040554A (ko) 티에노피리미딘-기초한 ｓｒｃ 계통군의 저해물질
Gable et al. Diarylureas are small-molecule inhibitors of insulin-like growth factor I receptor signaling and breast cancer cell growth
JP2002538107A (ja) アレルギー障害治療用のｊａｋ−３阻害剤
TW200808311A (en) Use of a kinase inhibitor for the treatment of particular resistant tumors
US10835525B2 (en) Method of inhibiting mutant C-KIT
Lee et al. Nicorandil regulates the macrophage skewing and ameliorates myofibroblasts by inhibition of RhoA/Rho‐kinase signalling in infarcted rats
US20230158034A1 (en) Co-treatment with cdk4/6 and cdk2 inhibitors to suppress tumor adaptation to cdk2 inhibitors
CN101222850A (zh) 治疗对药物有抗性的癌症的方法
KR20080027275A (ko) 암의 치료를 위한 4-아닐리노-3-퀴놀린카르보니트릴
US20230241052A1 (en) Method of inhibiting mutant c-kit
Khatri et al. Identification of alkynyl nicotinamide HSN748 as a RET solvent-front mutant inhibitor with intracranial efficacy
WO2008064004A2 (en) 4-anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (aml)
US20080119463A1 (en) 4-Anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (AML)
WO2008060283A1 (en) 4-anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (aml)
TW202425998A (zh) 併用醫藥
WO2024121437A1 (en) Small-molecule inhibitors of the frs2-fgfr interaction
AU2021288509A1 (en) Small-molecule inhibitors of the FRS2-FGFR interaction
HK1244482A1 (zh) 用於治疗神经母细胞瘤的组合
HK1244482B (zh) 用於治疗神经母细胞瘤的组合

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20071224

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid